Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

A. Pfeffer, Marc; Claggett, Brian; Díaz, Rafael; Dickstein, Kenneth; C. Gerstein, Hertzel; Køber, Lars; Lawson, Francesca; Ping, Lin; Wei, Xiaodan; F. Lewis, Eldrin; P. Maggioni, Aldo; J.V. McMurray, John; L. Probstfield, Jeffrey; C. Riddle, Matthew; D. Solomon, Scott; Tardif, Jean‐Claude

doi:10.1056/nejmoa1509225

Public

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Published in New England Journal of Medicine • Dec 2, 2015

Authors:

Marc A. Pfeffer

Brian Claggett

Rafael Díaz

Abstract

BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outco...

Subject

Lixisenatide

Acute coronary syndrome

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!